Kythera Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Calabasas CA United States (2005)
Status: Acquired by Allergan PLC (2015) (2015) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2007
NCT00422188
First Marketed Drug
2015
deoxycholic acid (kybella)
First NDA Approval
2015
deoxycholic acid (kybella)
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kythera Biopharmaceuticals | Kythera Biopharmaceuticals, Inc | Kythera Biopharmaceuticals, Inc. | KYTHERA BIOPHARMS

Indications

Approved Indications


 

Subcutaneous Fat

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lipoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 6